Aquilon is a specialty pharmaceutical company engaged in the development of drugs & improving the treatment of pulmonary diseases using the Value Added Medicines model.
Asthma and Chronic Obstructive Pulmonary Disease (COPD) are part of a group of lung diseases that obstruct airflow. Due to pollution, the global prevalence has skyrocketed. Nowadays, new geographical markets appear in the emerging economies due to pollution once again. Current drug treatments help to reduce the symptoms of asthma and COPD. The drug treatments for asthma and COPD are made of 3 components (formulation, carrier and device). Nevertheless, no optimal solution exists: (1) First, the traditional carriers do not distribute the drug homogeneously thus the treatments require high dose intake to work. Side-effects appear due to the high concentrations of drugs required to offset the misdistribution. The low efficiency of traditional carriers leads to important side-effects for the patient with limited efficacy; (2) Then, the prevailing devices are not user friendly or cannot contain the best treatments on the market; (3) Finally, inconsistent doses are delivered as it is highly dependent on inspiratory efforts from patients. There is still room for improvement in the prevailing treatments.
Aquilon Pharma intends to create value added medicines by combining the cyclodextrin with the most efficient active molecules and the best-known device available on the market. The carrier can be added to every treatment available on the market to improve their efficacy.